Do you think the new Wegovy weight-loss pill is a game-changer for obesity treatment?
FDA Approves First Oral Wegovy Pill for Weight Loss in U.S.
In January 2026, Novo Nordisk launched the first-ever oral version of Wegovy, a GLP-1 receptor agonist initially approved as an injection for weight loss. The daily pill, which helps control appetite and promotes significant weight loss, recently received FDA approval and is now available in U.S. pharmacies. Its launch marks a milestone in obesity treatment, offering a more convenient alternative to injections. The medication, which can cost as low as $149/month without insurance, is expected to reshape the weight-loss drug market and intensify competition with rivals like Eli Lilly. Clinical trials have shown patients can lose up to 17% of their body weight. The Wegovy pill also offers added benefits, such as reducing cardiovascular risk in certain patients. However, it carries common side effects like nausea, diarrhea, and fatigue. The oral version may open access to millions of patients who were reluctant to take injectable treatments.
Options
- Yes, it's a breakthrough
- No, it's overhyped
- Maybe, depends on side effects
- Haven’t heard of it